Physician

Holavanahall S Keshava-Prasad, MD

According to 2025 Medicare claims, Holavanahall Keshava-Prasad, MD (NPI: 1437100773) practices hematology/oncology in the Las Vegas-Henderson-North Las Vegas, NV market, with the plurality of this provider's patient population coming from Clark, NV. This provider's primary affiliated billing organization is ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (NPI: 1598770471; TIN: 88-0350180) and primary practice location at 89169-3321.

Keshava-Prasad's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 603 traditional Medicare patients, billed 182,072 HCPCS/CPT codes, and received $3,865,981 in Medicare payments. The top billing code was 78815 (Nuclear medicine study from skull base to mid-thigh with ct scan). Part D data shows 968 prescription claims across 152 beneficiaries totaling $2,709,565 in drug costs, led by Pomalyst (Pomalidomide). 2023 DME data shows 27 claims. Open Payments data shows 185 records totaling $20,445. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $1,625,297 to $3,865,981. Similarly, Part D prescription costs have risen steadily, from $239,560 to $2,709,565. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,636 to $578.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	662	134,572	$1,625,297
2016	773	177,222	$2,287,415
2017	740	196,039	$2,683,542
2018	644	161,053	$3,673,211
2019	785	225,104	$3,797,616
2020	734	172,476	$3,465,500
2021	690	162,593	$3,440,522
2022	715	184,836	$3,747,423
2023	627	230,271	$3,574,135
2024	603	182,072	$3,865,981

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	171	1,520	$239,560
2016	152	1,214	$625,486
2017	180	1,354	$1,107,779
2018	149	1,211	$1,156,558
2019	155	1,018	$1,299,595
2020	144	1,055	$765,816
2021	165	1,132	$1,052,576
2022	152	964	$1,466,996
2023	161	1,019	$3,290,960
2024	152	968	$2,709,565

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	83	$3,648
2016	N/R	71	$3,126
2017	N/R	61	$2,222
2018	N/R	21	$1,252
2019	N/R	N/R	N/R
2020	N/R	23	$802
2021	N/R	N/R	N/R
2022	N/R	45	$2,081
2023	N/R	27	$1,320
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
78815	Nuclear medicine study from skull base to mid-thigh with ct scan	119	129	$1,329
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	241	576	$92
80053	Blood test, comprehensive group of blood chemicals	258	889	$10
36415	Insertion of needle into vein for collection of blood sample	266	1,052	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	270	1,130	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pomalyst	Pomalidomide	28	784	$617,034
Erleada	Apalutamide	16	600	$274,884
Orenitram Er	Treprostinil Diolamine	12	360	$179,313
Promacta	Eltrombopag Olamine	22	660	$165,446
Venclexta	Venetoclax	13	376	$133,599

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	182	$12,105	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	3	$8,340	Epizyme, Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Holavanahall S. Keshava-Prasad, MD?

Tedicare shows public-source Medicare data for Holavanahall S. Keshava-Prasad, MD (NPI 1437100773), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Holavanahall S. Keshava-Prasad, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Holavanahall S. Keshava-Prasad, MD?

Holavanahall S. Keshava-Prasad, MD is linked to ALLISON CURTIS KINGSLEY MEOZ MICHAEL & SANCHEZ PC (billing NPI 1598770471) in the available physician profile data.

Does Holavanahall S. Keshava-Prasad, MD have Open Payments data?

Holavanahall S. Keshava-Prasad, MD has 185 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.